Welcome to BioSeeker Group!

A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market

Additional Information

Published Date May 24, 2010
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 838
PDF Fact Sheet View Fact Sheet for the report A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$1,950.00

Quick Overview

This report comprises defined and up to date development strategies for 346 prostate cancer drugs within the portfolio of 198 investigators, from Ceased to Marketed. The report extensively analyses 202 identified targets of prostate cancer drugs, organized into 187 drug target strategies, and assesses them in prostate cancer. Significantly new prostate cancer therapies will soon come to challenge old established drugs on the market. Four out of five target strategies in Phase III and nine out of ten in Phase II are novel and innovative in their design.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market.

    To find out more about A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This report comprises defined and up to date development strategies for 346 prostate cancer drugs within the portfolio of 198 investigators, from Ceased to Marketed. The report extensively analyses 202 identified targets of prostate cancer drugs, organized into 187 drug target strategies, and assesses them in prostate cancer. Significantly new prostate cancer therapies will soon come to challenge old established drugs on the market. Four out of five target strategies in Phase III and nine out of ten in Phase II are novel and innovative in their design.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in prostate cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any prostate cancer drug to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3
2 About Cancer Highlights™ 4
2.1 Cancer Focus Areas 4
2.2 Subscribe Today and Start Saving 5
2.2.1 Type of License 5
2.3 BioSeeker Group’s Oncology Team 5
3 Methodology 6
3.1 Cancer Highlights’™ Five Pillar Assessment 6
4 Table of Contents 8
4.1 List of Figures 19
4.2 List of Tables 20
5 Introduction 28
5.1 The Scope of this Report 28
5.2 Definitions 31
5.3 Abbreviations 31
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment 32
6.1 Drug Repositioning in Oncology 32
6.2 Introduction to Prostate Cancer Therapeutic Targets in Oncology 33
6.2.1 Acid Phosphatase Activity Targets 36
6.2.2 Calcium Ion Binding Targets 37
6.2.3 Carboxy-lyase Activity Targets 38
6.2.4 Carboxypeptidase Activity Targets 39
6.2.5 Catalytic Activity Targets 41
6.2.6 Cell Adhesion Molecule Activity Targets 54
6.2.7 Chaperone Activity Targets 60
6.2.8 Chemokine Activity Targets 63
6.2.9 Complement Activity Targets 65
6.2.10 Cysteine-type Peptidase Activity Targets 68
6.2.11 Cytokine Activity Targets 71
6.2.12 DNA Binding Targets 78
6.2.13 DNA Repair Protein Targets 79
6.2.14 DNA Topoisomerase Activity Targets 80
6.2.15 DNA-directed DNA Polymerase Activity Targets 84
6.2.16 Extracellular Ligand-gated Ion Channel Activity Targets 90
6.2.17 G-protein Coupled Receptor Activity Targets 92
6.2.18 Growth Factor Activity Targets 102
6.2.19 GTPase Activator Activity Targets 110
6.2.20 Hormone Activity Targets 111
6.2.21 Hydrolase Activity Targets 112
6.2.22 Ion Channel Activity Targets 113
6.2.23 Isomerase Activity Targets 114
6.2.24 Kinase Activity Targets 115
6.2.25 Kinase Regulator Activity Targets 123
6.2.26 Ligand-dependent Nuclear Receptor Activity Targets 124
6.2.27 Ligase Activity Targets 127
6.2.28 Lipid Kinase Activity Targets 130
6.2.29 Lipid Phosphatase Activity Targets 136
6.2.30 Metallopeptidase Activity Targets 137
6.2.31 MHC Class I Receptor Activity Targets 140
6.2.32 Motor Activity Targets 150
6.2.33 Oxidoreductase Activity Targets 151
6.2.34 Peptidase Activity Targets 157
6.2.35 Peptide Hormone Targets 160
6.2.36 Peroxidase Activity Targets 161
6.2.37 Phosphoric Diester Hydrolase Activity Targets 162
6.2.38 Protein Binding Targets 164
6.2.39 Protein Serine/Threonine Kinase Activity Targets 166
6.2.40 Protein Serine/Threonine kinase activity Targets 168
6.2.41 Protein-tyrosine Kinase Activity Targets 191
6.2.42 Receptor Activity Targets 203
6.2.43 Receptor Binding Targets 219
6.2.44 Receptor Signaling Complex Scaffold Activity Targets 222
6.2.45 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 228
6.2.46 RNA Binding Targets 229
6.2.47 RNA-directed DNA Polymerase Activity Targets 230
6.2.48 Serine-type Peptidase Activity Targets 231
6.2.49 Structural Constituent of Cytoskeleton Targets 236
6.2.50 Superoxide Dismutase Activity Targets 237
6.2.51 Transcription Factor Activity Targets 241
6.2.52 Transcription Regulator Activity Targets 260
6.2.53 Translation Regulator Activity Targets 265
6.2.54 Transmembrane Receptor Activity Targets 267
6.2.55 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 272
6.2.56 Transporter Activity Targets 298
6.2.57 Ubiquitin-specific Protease Activity Targets 302
6.2.58 Voltage-gated Ion Channel Activity Targets 304
6.2.59 Other Targets 305
6.3 The Cancer Genome Project and Prostate Cancer Therapeutic Targets 306
6.3.1 Prostate Cancer Therapeutic Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 306
6.4 Structure-based Drug Design in Prostate Cancer Therapeutics is Stimulated by Available Structure Data on Biological Targets 312
6.5 Target-Target Interactions among Identified Therapeutics Targets in Prostate Cancer 316
6.6 The Drug-Target Interactome 322
6.7 Protein Expression Levels of Identified Targets of Prostate Cancer Drugs 327
6.8 Pathway Assessment of Prostate Cancer Therapeutic Targets 332
6.8.1 Tools for Analysis of Cancer Pathways 333
6.8.2 Pathway Assessment 334
7 Emerging New Products to Established Ones: Drug Target Strategies by their Highest Stage of Development in the Prostate Cancer Pipeline 384
7.1 Terminated Drug Target Strategies of Prostate Cancer Drugs 388
7.2 Pre-registration to being Marketed: New and Unique Drug Target Strategies of Prostate Cancer Therapeutics 392
7.3 Phase III Clinical Development: New and Unique Drug Target Strategies of Prostate Cancer Therapeutics 394
7.4 Phase II Clinical Development: New and Unique Drug Target Strategies of Prostate Cancer Therapeutics 396
7.5 Phase I Clinical Development: New and Unique Drug Target Strategies of Prostate Cancer Therapeutics 401
7.6 Preclinical Development: New and Unique Drug Target Strategies of Prostate Cancer Therapeutics 404
7.7 No Development Data: New and Unique Drug Target Strategies of Prostate Cancer Therapeutics 407
7.8 Development Profiles of All Prostate Cancer Drugs in Oncology 409
7.9 The Competition Through Close Mechanistic Approximation of Prostate Cancer Therapeutics 432
8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy 439
8.1 Small Molecules 441
8.1.1 Background 441
8.1.2 Target Strategies of Small Molecular Drugs 442
8.2 Peptide/Protein Drugs 454
8.2.1 Background 454
8.2.2 Target Strategies of Peptide and Protein Drugs 455
8.3 Antibodies and Antibody-like Structures 462
8.3.1 Background 462
8.3.2 Target Strategies of Antibody Drugs 462
8.4 Nucleic Acid Therapies 466
8.4.1 Background 466
8.4.2 Target Strategies of Nucleic Acid Drugs 467
8.5 Cell and Gene Therapy 470
8.5.1 Background 470
8.5.2 Target Strategies of Cell- and Gene Therapy Drugs 472
8.6 Drug Delivery and Nanotechnology 476
8.6.1 Background 476
8.6.2 Target Strategies of Reformulated Drugs 476
8.7 Compound Strategies based on Sub-Cellular Localization of Prostate Cancer Drug Targets 479
9 Pipeline and Portfolio Planning: Competitive Benchmarking of Prostate Cancer Cancer Therapeutic Pipeline by Investigator 486
9.1 Competitive Fall-Out Assessment 486
9.2 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 487
9.3 Abbott 489
9.4 Abraxis BioScience 491
9.5 Active Biotech 493
9.6 Advantagene 494
9.7 AEgera 495
9.8 Aeterna Zentaris 496
9.9 Alchemia 501
9.10 Allos Therapeutics 502
9.11 AlphaVax 503
9.12 Alseres Pharmaceuticals 504
9.13 Altor BioScience 506
9.14 Ambrilia Biopharma 507
9.15 Amgen 509
9.16 Anavex Life Sciences 511
9.17 AndroBioSys 512
9.18 Antisense Pharma 514
9.19 Antisense Therapeutics 515
9.20 Antisoma 516
9.21 Aphios 519
9.22 ApopLogic Pharmaceuticals 520
9.23 Apotex 522
9.24 Apthera 523
9.25 Archer Biosciences 524
9.26 Ardana 525
9.27 Ariad 528
9.28 ArQule 529
9.29 Array BioPharma 530
9.30 Ascenta Therapeutics 531
9.31 Astellas 532
9.32 AstraZeneca 535
9.33 Attenuon 542
9.34 AVI BioPharma 543
9.35 Bavarian Nordic 544
9.36 Baxter International 546
9.37 Bayer 548
9.38 Bellicum Pharmaceuticals 551
9.39 Bioenvision 552
9.40 Biogen Idec 554
9.41 BioLineRx 555
9.42 BioNetWorks 556
9.43 Biostar 557
9.44 Boehringer Ingelheim 558
9.45 Bristol-Myers Squibb 560
9.46 BTG 567
9.47 Cadila 568
9.48 Camurus 570
9.49 Cancer Research Technology 572
9.50 Cel-Sci 575
9.51 Cell Genesys 576
9.52 Cell Therapeutics 577
9.53 Celldex Therapeutics 579
9.54 Celsion 581
9.55 Center of Molecular Immunology 582
9.56 Cephalon 583
9.57 ChemGenex Pharmaceuticals 585
9.58 Chemokine Therapeutics 586
9.59 Circadian Technologies 587
9.60 Cleveland BioLabs 588
9.61 Colby 589
9.62 Cylene Pharmaceuticals 591
9.63 Cytokinetics 592
9.64 Daiichi Sankyo 593
9.65 Debiopharm 594
9.66 Dendreon 598
9.67 Dongkook Pharm 599
9.68 ECI 602
9.69 Eisai 603
9.70 Elan 605
9.71 Eli Lilly 606
9.72 Endo Pharmaceuticals 610
9.73 Endocyte 612
9.74 Ensemble Discovery 613
9.75 EntreMed 614
9.76 EpiCept 615
9.77 EUSA Pharma 616
9.78 Exelixis 618
9.79 Ferring 621
9.80 Gemin X Biotechnologies 623
9.81 Generex 624
9.82 GENova Biotherapeutics 625
9.83 Genta 626
9.84 Genzyme 627
9.85 Gerolymatos 629
9.86 Geron 631
9.87 GlaxoSmithKline 633
9.88 Gloucester Pharmaceuticals 635
9.89 GlycoGenesys 636
9.90 Got-a-Gene 637
9.91 GP Pharm 639
9.92 Green Cross 641
9.93 GTx 642
9.94 Harbor BioSciences 644
9.95 Hoffmann-La Roche 646
9.96 Human Genome Sciences 651
9.97 Hybrigenics 652
9.98 Immunocore 653
9.99 ImmunoGen 654
9.100 Immunomedics 656
9.101 Incyte Corporation 657
9.102 Infinity Pharmaceuticals 659
9.103 Inovio 660
9.104 Insmed 662
9.105 Introgen Therapeutics 663
9.106 Ipsen 664
9.107 Isis Pharmaceuticals 666
9.108 Ivy Medical Chemicals 667
9.109 Johnson & Johnson 668
9.110 Karo Bio 674
9.111 Kyowa Hakko Kirin 676
9.112 LEAD Therapeutics 678
9.113 Ligand 679
9.114 Lorus Therapeutics 681
9.115 Mannkind 683
9.116 Marillion Pharmaceuticals 684
9.117 Med Discovery 685
9.118 Medarex 686
9.119 MediGene 688
9.120 MedImmune 690
9.121 Mediolanum 691
9.122 Medivation 693
9.123 Menarini 695
9.124 Merck & Co 696
9.125 Merck KGaA 698
9.126 Merrion Pharmaceuticals 700
9.127 MethylGene 702
9.128 Micromet 703
9.129 Mojave Therapeutics 705
9.130 Nektar Therapeutics 706
9.131 NeoPharm 708
9.132 Nerviano Medical Sciences 710
9.133 Nippon Shinyaku 711
9.134 Non-industrial Sources 712
9.135 Northwest Biotherapeutics 714
9.136 Norwood Abbey 715
9.137 Novacea 717
9.138 Novartis 718
9.139 Novogen 724
9.140 OncoGenex Pharmaceuticals 725
9.141 Oncothyreon 727
9.142 Oncovir 728
9.143 Orion Pharma 729
9.144 OSI Pharmaceuticals 731
9.145 Oxford BioMedica 734
9.146 Paladin Labs 735
9.147 Pantarhei Bioscience 736
9.148 Pepscan Therapeutics 737
9.149 Pfizer 738
9.150 Pharmacyclics 745
9.151 PharmaGap 746
9.152 PharmaMar 747
9.153 Pierre Fabre 748
9.154 Progen 750
9.155 Progenics Pharmaceuticals 751
9.156 ProNAi Therapeutics 754
9.157 ProStrakan 755
9.158 Protox Therapeutics 757
9.159 Q Chip 759
9.160 QLT 761
9.161 Receptor BioLogix 763
9.162 Regeneron 764
9.163 Regulon 765
9.164 Rexahn 766
9.165 Samyang 767
9.166 Sanofi-Aventis 768
9.167 Santaris Pharma 773
9.168 Sapphire Therapeutics 775
9.169 Semafore Pharmaceuticals 776
9.170 Serometrix 777
9.171 SGX Pharmaceuticals 779
9.172 Shire 780
9.173 Soligenix 782
9.174 SRI International 784
9.175 SuperGen 785
9.176 Supratek Pharma 788
9.177 Switch Pharma 789
9.178 Takeda 790
9.179 Tau Therapeutics 793
9.180 Thallion Pharmaceuticals 794
9.181 Therion Biologics 795
9.182 Titan Pharmaceuticals 797
9.183 Tokai Pharmaceuticals 798
9.184 TopoTarget 799
9.185 Transgene 801
9.186 Twinstrand Therapeutics 802
9.187 Unigene 803
9.188 United Biomedical 805
9.189 Vaxon Biotech 807
9.190 Velacor Therapeutics 808
9.191 Vion Pharmaceuticals 809
9.192 VioQuest 811
9.193 Viralytics 812
9.194 ViroTarg 814
9.195 VM Discovery 815
9.196 Wilex 816
9.197 Xerion 817
9.198 Xoma 819
9.199 YM BioSciences 820
10 Disclaimer 821
11 Drug Index 822
12 Company Index 831

Figure 1: Visualization of Target-Target Interactions among Targets of Prostate Cancer Drugs 321
Figure 2: The Drug-Target Interactions of Prostate Cancer Drugs - Large Clusters 323
Figure 3: The Drug-Target Interactions of Prostate Cancer Drugs - Smaller Clusters 324
Figure 4: Head-to-Head Targeting Interactions of Prostate Cancer Drugs – Larger Clusters 325
Figure 5: Head-to-Head Targeting Interactions of Prostate Cancer Drugs – Smaller Clusters 326
Figure 6: Primary Sub-cellular Localization of Drug Targets 479
Table 1: Cancer Highlights’™ Five Pillar Assessment 6
Table 2: Breakdown of the Included Prostate Cancer Pipeline by Stage of Development 28
Table 3: Head to Head Target Competition among Prostate Cancer Drugs 28
Table 4: Overview of Drug Target Strategy Themes 33
Table 5: Terminally Ceased Therapeutic Prostate Cancer Targets 34
Table 6: Drug Targets of Prostate Cancer Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 307
Table 7: Identity of Prostate Cancer Drug Targets with Available Biological Structures 312
Table 8: Number of Target-Target Interactions among Targets of Prostate Cancer Drugs 316
Table 9: Prostate Cancer Drug Targets with Available Protein Expression Profiles 327
Table 10: Pathway Summary 334
Table 11: Drug Targets without any Identified Assigned Pathways 334
Table 12: Pathway Profiles According to BioCarta of Prostate Cancer Drug Targets 336
Table 13: Pathway Profiles According to KEGG of Prostate Cancer Drug Targets 356
Table 14: Pathway Profiles According to NetPath of Prostate Cancer Drug Targets 379
Table 15: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 384
Table 16: Top Competitive Target Strategies in Prostate Cancer 385
Table 17: Terminated Drug Target Strategies of Prostate Cancer Drugs 389
Table 18: New and Unique Target Strategies in Prostate Cancer Currently in Pre-registration to Marketed 392
Table 19: The Competition Through Close Mechanistic Approximation Between Pre-registration to Marketed Drugs in Prostate Cancer 393
Table 20: New and Unique Prostate Cancer Target Strategies in Phase III Clinical Development 394
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Drugs in Prostate Cancer 395
Table 22: New and Unique Prostate Cancer Target Strategies in Phase II Clinical Development 396
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Drugs in Prostate Cancer 399
Table 24 New and Unique Prostate Cancer Target Strategies in Phase I Clinical Development 401
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Drugs in Prostate Cancer 403
Table 26: New and Unique Prostate Cancer Target Strategies in Preclinical Development 404
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Drugs in Prostate Cancer 406
Table 28: New and Unique Prostate Cancer Target Strategies in Unknown Developmental Stage 407
Table 29: The Competition Through Close Mechanistic Approximation Between Drugs with No Developmental Data in Prostate Cancer 408
Table 30: The Progression, Maturity and Competitive Comparison of Target Strategies in Prostate Cancer Drug Development 409
Table 31: The Competition Through Close Mechanistic Approximation Among All Drugs in Prostate Cancer 432
Table 32: Overview of Compound Strategy Competition Among Prostate Cancer Drugs 440
Table 33: Overview of the Competitive Landscape of Small Molecule Prostate Cancer Drugs 442
Table 34: The Competition Through Close Mechanistic Approximation between Small Molecule Drugs in Prostate Cancer 443
Table 35: Competitive Comparison of Target Strategies of Small Molecule Drugs in Prostate Cancer 446
Table 36: Overview of the Competitive Landscape of Peptide Based Drugs in Prostate Cancer 455
Table 37: The Competition Through Close Mechanistic Approximation between Peptide Based Drugs in Prostate Cancer 456
Table 38: Competitive Comparison of Target Strategies of Peptide Based Drugs in Prostate Cancer 457
Table 39: Overview of the Competitive Landscape of Protein Based Drugs in Prostate Cancer 459
Table 40: The Competition Through Close Mechanistic Approximation between Protein Based Drugs in Prostate Cancer 460
Table 41: Competitive Comparison of Target Strategies of Protein Based Drugs in Prostate Cancer 460
Table 42: Overview of the Competitive Landscape of Antibody Drugs in Prostate Cancer 462
Table 43: The Competition Through Close Mechanistic Approximation between Antibody Drugs in Prostate Cancer 463
Table 44: Competitive Comparison of Target Strategies of Antibody Drugs in Prostate Cancer 464
Table 45: Overview of the Competitive Landscape of Nucleic Acid Therapy Drugs in Prostate Cancer 467
Table 46: The Competition Through Close Mechanistic Approximation between Nucleic Acid Therapy Drugs in Prostate Cancer 468
Table 47: Competitive Comparison of Target Strategies of Nucleic Acid Drugs in Prostate Cancer 468
Table 48: Potential Forms of Cell Therapy 470
Table 49: Vectors in Gene Therapy 471
Table 50: Overview of the Competitive Landscape of Cell Therapy based Drugs in Prostate Cancer 472
Table 51: The Competition Through Close Mechanistic Approximation between Cell Therapy Drugs in Prostate Cancer 473
Table 52: Competitive Comparison of Target Strategies of Cell Therapy Based Drugs in Prostate Cancer 473
Table 53: Overview of the Competitive Landscape of Gene Therapy based Drugs in Prostate Cancer 474
Table 54: The Competition Through Close Mechanistic Approximation between Gene Therapy Drugs in Prostate Cancer 475
Table 55: Competitive Comparison of Target Strategies of Gene Therapy Based Drugs in Prostate Cancer 475
Table 56:Overview of the Competitive Landscape of Reformulated Drugs in Prostate Cancer 476
Table 57: The Competition Through Close Mechanistic Approximation between Reformulated Drugs in Prostate Cancer 477
Table 58: Competitive Comparison of Target Strategies of Reformulated Drugs in Prostate Cancer 478
Table 59: Compound Strategies based on Sub-Cellular Localization of Prostate Cancer Drug Targets 480
Table 60: Summary Table of Changes in the Competitive Landscape of Prostate Cancer Drug Development 487
Table 61: Abbott’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 489
Table 62: Abraxis BioScience’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 491
Table 63: Active Biotech’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 493
Table 64: Advantagene’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 494
Table 65: AEgera’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 495
Table 66: Aeterna Zentaris’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 496
Table 67: Alchemia’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 501
Table 68: Allos Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 502
Table 69: AlphaVax’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 503
Table 70: Alseres Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 504
Table 71: Altor BioScience’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 506
Table 72: Ambrilia Biopharma’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 507
Table 73: Amgen’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 509
Table 74: Anavex Life Sciences’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 511
Table 75: AndroBioSys’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 512
Table 76: Antisense Pharma’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 514
Table 77: Antisense Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 515
Table 78: Antisoma’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 516
Table 79: Aphios’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 519
Table 80: ApopLogic Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 520
Table 81: Apotex’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 522
Table 82: Apthera’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 523
Table 83: Archer Biosciences’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 524
Table 84: Ardana’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 525
Table 85: Ariad’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 528
Table 86: ArQule’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 529
Table 87: Array BioPharma’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 530
Table 88: Ascenta Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 531
Table 89: Astellas’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 532
Table 90: AstraZeneca’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 535
Table 91: Attenuon’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 542
Table 92: AVI BioPharma’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 543
Table 93: Bavarian Nordic’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 544
Table 94: Baxter International’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 546
Table 95: Bayer’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 548
Table 96: Bellicum Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 551
Table 97: Bioenvision’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 552
Table 98: Biogen Idec’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 554
Table 99: BioLineRx’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 555
Table 100: BioNetWorks’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 556
Table 101: Biostar’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 557
Table 102: Boehringer Ingelheim’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 558
Table 103: Bristol-Myers Squibb’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 560
Table 104: BTG’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 567
Table 105: Cadila’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 568
Table 106: Camurus’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 570
Table 107: Cancer Research Technology’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 572
Table 108: Cel-Sci’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 575
Table 109: Cell Genesys’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 576
Table 110: Cell Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 577
Table 111: Celldex Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 579
Table 112: Celsion’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 581
Table 113: Center of Molecular Immunology’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 582
Table 114: Cephalon’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 583
Table 115: ChemGenex Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 585
Table 116: Chemokine Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 586
Table 117: Circadian Technologies’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 587
Table 118: Cleveland BioLabs’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 588
Table 119: Colby’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 589
Table 120: Cylene Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 591
Table 121: Cytokinetics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 592
Table 122: Daiichi Sankyo’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 593
Table 123: Debiopharm’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 594
Table 124: Dendreon’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 598
Table 125: Dongkook Pharm’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 599
Table 126: ECI’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 602
Table 127: Eisai’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 603
Table 128: Elan’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 605
Table 129: Eli Lilly’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 606
Table 130: Endo Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 610
Table 131: Endocyte’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 612
Table 132: Ensemble Discovery’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 613
Table 133: EntreMed’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 614
Table 134: EpiCept’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 615
Table 135: EUSA Pharma’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 616
Table 136: Exelixis’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 618
Table 137: Ferring’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 621
Table 138: Gemin X Biotechnologies’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 623
Table 139: Generex’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 624
Table 140: GENova Biotherapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 625
Table 141: Genta’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 626
Table 142: Genzyme’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 627
Table 143: Gerolymatos’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 629
Table 144: Geron’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 631
Table 145: GlaxoSmithKline’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 633
Table 146: Gloucester Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 635
Table 147: GlycoGenesys’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 636
Table 148: Got-a-Gene’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 637
Table 149: GP Pharm’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 639
Table 150: Green Cross’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 641
Table 151: GTx’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 642
Table 152: Harbor BioSciences’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 644
Table 153: Hoffmann-La Roche’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 646
Table 154: Human Genome Sciences’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 651
Table 155: Hybrigenics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 652
Table 156: Immunocore’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 653
Table 157: ImmunoGen’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 654
Table 158: Immunomedics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 656
Table 159: Incyte Corporation’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 657
Table 160: Infinity Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 659
Table 161: Inovio’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 660
Table 162: Insmed’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 662
Table 163: Introgen Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 663
Table 164: Ipsen’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 664
Table 165: Isis Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 666
Table 166: Ivy Medical Chemicals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 667
Table 167: Johnson & Johnson’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 668
Table 168: Karo Bio’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 674
Table 169: Kyowa Hakko Kirin’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 676
Table 170: LEAD Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 678
Table 171: Ligand’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 679
Table 172: Lorus Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 681
Table 173: Mannkind’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 683
Table 174: Marillion Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 684
Table 175: Med Discovery’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 685
Table 176: Medarex’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 686
Table 177: MediGene’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 688
Table 178: MedImmune’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 690
Table 179: Mediolanum’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 691
Table 180: Medivation’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 693
Table 181: Menarini’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 695
Table 182: Merck & Co’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 696
Table 183: Merck KGaA’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 698
Table 184: Merrion Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 700
Table 185: MethylGene’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 702
Table 186: Micromet’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 703
Table 187: Mojave Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 705
Table 188: Nektar Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 706
Table 189: NeoPharm’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 708
Table 190: Nerviano Medical Sciences’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 710
Table 191: Nippon Shinyaku’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 711
Table 192: Non-industrial source’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 712
Table 193: Northwest Biotherapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 714
Table 194: Norwood Abbey’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 715
Table 195: Novacea’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 717
Table 196: Novartis’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 718
Table 197: Novogen’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 724
Table 198: OncoGenex Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 725
Table 199: Oncothyreon’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 727
Table 200: Oncovir’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 728
Table 201: Orion Pharma’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 729
Table 202: OSI Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 731
Table 203: Oxford BioMedica’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 734
Table 204: Paladin Labs’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 735
Table 205: Pantarhei Bioscience’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 736
Table 206: Pepscan Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 737
Table 207: Pfizer’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 738
Table 208: Pharmacyclics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 745
Table 209: PharmaGap’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 746
Table 210: PharmaMar’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 747
Table 211: Pierre Fabre’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 748
Table 212: Progen’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 750
Table 213: Progenics Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 751
Table 214: ProNAi Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 754
Table 215: ProStrakan’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 755
Table 216: Protox Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 757
Table 217: Q Chip’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 759
Table 218: QLT’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 761
Table 219: Receptor BioLogix’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 763
Table 220: Regeneron’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 764
Table 221: Regulon’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 765
Table 222: Rexahn’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 766
Table 223: Samyang’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 767
Table 224: Sanofi-Aventis’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 768
Table 225: Santaris Pharma’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 773
Table 226: Sapphire Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 775
Table 227: Semafore Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 776
Table 228: Serometrix’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 777
Table 229: SGX Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 779
Table 230: Shire’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 780
Table 231: Soligenix’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 782
Table 232: SRI International’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 784
Table 233: SuperGen’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 785
Table 234: Supratek Pharma’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 788
Table 235: Switch Pharma’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 789
Table 236: Takeda’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 790
Table 237: Tau Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 793
Table 238: Thallion Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 794
Table 239: Therion Biologics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 795
Table 240: Titan Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 797
Table 241: Tokai Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 798
Table 242: TopoTarget’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 799
Table 243: Transgene’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 801
Table 244: Twinstrand Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 802
Table 245: Unigene’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 803
Table 246: United Biomedical’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 805
Table 247: Vaxon Biotech’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 807
Table 248: Velacor Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 808
Table 249: Vion Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 809
Table 250: VioQuest’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 811
Table 251: Viralytics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 812
Table 252: ViroTarg’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 814
Table 253: VM Discovery’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 815
Table 254: Wilex’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 816
Table 255: Xerion’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 817
Table 256: Xoma’s Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 819
Table 257: YM BioSciences’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out 820

This report includes 198 investigators plus their collaborators:
Abbott
Abraxis BioScience
Active Biotech
Advantagene
AEgera
Aeterna Zentaris
Alchemia
Allos Therapeutics
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambrilia Biopharma
Amgen
Anavex Life Sciences
AndroBioSys
Antisense Pharma
Antisense Therapeutics
Antisoma
Aphios
ApopLogic Pharmaceuticals
Apotex
Apthera
Archer Biosciences
Ardana
Ariad
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
AstraZeneca
Attenuon
AVI BioPharma
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
Bioenvision
Biogen Idec
BioLineRx
BioNetWorks
Biostar
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Cadila
Camurus
Cancer Research Technology
Cell Genesys
Cell Therapeutics
Celldex Therapeutics
Cel-Sci
Celsion
Center of Molecular Immunology
Cephalon
ChemGenex Pharmaceuticals
Chemokine Therapeutics
Circadian Technologies
Cleveland BioLabs
Colby
Cylene Pharmaceuticals
Cytokinetics
Daiichi Sankyo
Debiopharm
Dendreon
Dongkook Pharm
ECI
Eisai
Elan
Eli Lilly
Endo Pharmaceuticals
Endocyte
Ensemble Discovery
EntreMed
EpiCept
EUSA Pharma
Exelixis
Ferring
Gemin X Biotechnologies
Generex
GENova Biotherapeutics
Genta
Genzyme
Gerolymatos
Geron
GlaxoSmithKline
Gloucester Pharmaceuticals
GlycoGenesys
Got-a-Gene
GP Pharm
Green Cross
GTx
Harbor BioSciences
Hoffmann-La Roche
Human Genome Sciences
Hybrigenics
Immunocore
ImmunoGen
Immunomedics
Incyte Corporation
Infinity Pharmaceuticals
Inovio
Insmed
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
Ivy Medical Chemicals
Johnson & Johnson
Karo Bio
Kyowa Hakko Kirin
LEAD Therapeutics
Ligand
Lorus Therapeutics
Mannkind
Marillion Pharmaceuticals
Med Discovery
Medarex
MediGene
MedImmune
Mediolanum
Medivation
Menarini
Merck & Co
Merck KGaA
Merrion Pharmaceuticals
MethylGene
Micromet
Mojave Therapeutics
Nektar Therapeutics
NeoPharm
Nerviano Medical Sciences
Nippon Shinyaku
Northwest Biotherapeutics
Norwood Abbey
Novacea
Novartis
Novogen
OncoGenex Pharmaceuticals
Oncothyreon
Oncovir
Orion Pharma
OSI Pharmaceuticals
Oxford BioMedica
Paladin Labs
Pantarhei Bioscience
Pepscan Therapeutics
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pierre Fabre
Progen
Progenics Pharmaceuticals
ProNAi Therapeutics
ProStrakan
Protox Therapeutics
Q Chip
QLT
Receptor BioLogix
Regeneron
Regulon
Rexahn
Samyang
Sanofi-Aventis
Santaris Pharma
Sapphire Therapeutics
Semafore Pharmaceuticals
Serometrix
SGX Pharmaceuticals
Shire
Soligenix
SRI International
SuperGen
Supratek Pharma
Switch Pharma
Takeda
Tau Therapeutics
Thallion Pharmaceuticals
Therion Biologics
Titan Pharmaceuticals
Tokai Pharmaceuticals
TopoTarget
Transgene
Twinstrand Therapeutics
Unigene
United Biomedical
Vaxon Biotech
Velacor Therapeutics
Wilex
Vion Pharmaceuticals
VioQuest
Viralytics
ViroTarg
VM Discovery
Xerion
Xoma
YM BioSciences
This report includes 346 prostate cancer drugs. From Ceased to Marketed.
A shortlist of drugs included are:
abarelix
abiraterone acetate
aflibercept
bevacizumab
bicalutamide
buserelin
celecoxib
dasatinib
DCVax-prostate
degarelix
denosumab
deslorelin
docetaxel
dutasteride
estramustine phosphate sodium
ethinyl estradiol sulfonate
flutamide
goserelin
histrelin
ipilimumab
leuprolide
MDV-3100
nadroparin
nilutamide
sunitinib malate
toremifene citrate
triptorelin pamoate
triptorelin
zibotentan

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market.
    To find out more about A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize?
This report is an important part of creating and implementing a market development plan for any cancer therapeutic peptide drugs to ensure that the optimal market conditions exist by the time the product is commercialized. Learn More


Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology
This report is written for you to identify your competition and understand which targeting strategies are at work within anti-angiogenic drug development in oncology. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversly it may reveal unexpected competition for you. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Colorectal Cancer, Angiogenesis and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Learn More


Triple Analysis: Breast Cancer, Pancreatic Cancer and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Pancreatic Cancer and by the mechanism/target/effect of Cancer Vaccines. Learn More